Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares

08:33 AM EDT, 08/24/2026 (MT Newswires) -- Arbutus Biopharma (ABUS) has commenced a tender offer to purchase for cancellation its common shares worth $230 million, pricing shares between $5.00 and $5.75 apiece, the company said Monday. The offer is slated to expire on Sept. 29, unless extended or terminated by the company, Arbutus Biopharma said. The clinical-stage biopharmaceutical further said that it intends to pay for the tender offer with available cash on hand, and that the offer is not tied to any financing requirements or any minimum number of shares being tendered. If fully subscribed, Arbutus said it expects to repurchase between 20.2% and 23.2% of its outstanding shares, based on its 198.1 million shares outstanding as of Aug. 19.